NO963483L - Nye indolderivater som er anvendbare for å behandle östrogen-relaterte neoplasmer og forstyrrelser - Google Patents

Nye indolderivater som er anvendbare for å behandle östrogen-relaterte neoplasmer og forstyrrelser

Info

Publication number
NO963483L
NO963483L NO963483A NO963483A NO963483L NO 963483 L NO963483 L NO 963483L NO 963483 A NO963483 A NO 963483A NO 963483 A NO963483 A NO 963483A NO 963483 L NO963483 L NO 963483L
Authority
NO
Norway
Prior art keywords
indole derivatives
derivatives useful
disorders
neoplasms
treating estrogen
Prior art date
Application number
NO963483A
Other languages
English (en)
Other versions
NO963483D0 (no
Inventor
Alan Joseph Bitonti
Ian Alexander Mcdonald
Francesco Gerald Salituro
Jeffrey Paul Whitten
Esa Tero Jarvi
Paul Steven Wright
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Publication of NO963483D0 publication Critical patent/NO963483D0/no
Publication of NO963483L publication Critical patent/NO963483L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Foreliggende oppfinnelse angår !nye indolderivater av formel (I) (CH2)p-C-N-(CHi)n-C---N som er anvendbare ved nedregulering av østrogenreseptorekspresjon. ; Også innbefattet er metoder for behandling av neoplasmer eller for regulering av veksten av en neo- plasme i en pasient angrepet av en neoplastisk sykdom, spesielt østrogen-avhengige neoplasmer slik som de som er assosiert med bryst-, ovarie-og cervikalt vev. En annen utførelsesform av foreliggende oppfinnelse er en metode for pro- fylaktisk behandling av en pasient med risiko for å utvikle en neo- plastisk sykdomstilstand. Også tilveiebragt er en metode for behandling av autoimmune sykdommer. Også innbefattet er farmasøytiske preparater av de nye indol- derivater.
NO963483A 1994-02-22 1996-08-21 Nye indolderivater som er anvendbare for å behandle östrogen-relaterte neoplasmer og forstyrrelser NO963483L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20005794A 1994-02-22 1994-02-22
US36204694A 1994-12-22 1994-12-22
PCT/US1995/001372 WO1995022524A1 (en) 1994-02-22 1995-01-31 Novel indole derivatives useful to treat estrogen-related neoplasms and disorders

Publications (2)

Publication Number Publication Date
NO963483D0 NO963483D0 (no) 1996-08-21
NO963483L true NO963483L (no) 1996-10-22

Family

ID=26895427

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963483A NO963483L (no) 1994-02-22 1996-08-21 Nye indolderivater som er anvendbare for å behandle östrogen-relaterte neoplasmer og forstyrrelser

Country Status (17)

Country Link
US (1) US5877202A (no)
EP (1) EP0746544B1 (no)
JP (1) JP3536258B2 (no)
KR (1) KR100362864B1 (no)
CN (1) CN1141627A (no)
AT (1) ATE170839T1 (no)
AU (1) AU680740B2 (no)
CA (1) CA2183731C (no)
DE (1) DE69504637T2 (no)
DK (1) DK0746544T3 (no)
ES (1) ES2122555T3 (no)
FI (1) FI963272A0 (no)
HU (1) HUT76133A (no)
IL (1) IL112700A0 (no)
NO (1) NO963483L (no)
NZ (1) NZ281431A (no)
WO (1) WO1995022524A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
AU6015098A (en) * 1997-02-24 1998-09-09 Cornell Research Foundation Inc. Method of screening agents as candidates for drugs or sources of drugs
US6150395A (en) * 1997-05-30 2000-11-21 The Regents Of The University Of California Indole-3-carbinol (I3C) derivatives and methods
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
JP2002515484A (ja) * 1998-05-15 2002-05-28 アメリカン・ホーム・プロダクツ・コーポレイション ２−フェニルインドール化合物およびエストロゲン製剤からなる組成物
US6207700B1 (en) * 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
US6159959A (en) * 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
BR0013943A (pt) * 1999-09-13 2002-05-14 American Home Prod Conjugados de glicopiranosìdeos de 2-(4-hidróxi-fenil)-1-[4-(2-amin-1-il-etóxi)-benzil]-1h-indo l-5-óis
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
WO2001058869A2 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US6326501B1 (en) * 2000-04-19 2001-12-04 Hoffmann-La Roche Inc. Methylation of indole compounds using dimethyl carbonate
AU2002211828A1 (en) * 2000-10-02 2002-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US20030130199A1 (en) * 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
FR2842526B1 (fr) 2002-07-16 2007-07-13 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments
CN1791402A (zh) * 2003-03-27 2006-06-21 麦克公司 治疗眼高压的眼科组合物
CA2562783A1 (en) 2004-04-26 2005-12-01 Vanderbilt University Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
WO2007013872A2 (en) * 2004-07-22 2007-02-01 The Board Of Trustees Of The University Of Illinois Sensors employing single-walled carbon nanotubes
WO2007062399A2 (en) 2005-11-23 2007-05-31 The Board Of Regents Of The University Of Texas System Oncogenic ras-specific cytotoxic compound and methods of use thereof
CA2777782C (en) 2009-10-15 2016-06-28 Children's Medical Center Corporation Sepiapterin reductase inhibitors for the treatment of pain
AU2011296103B2 (en) 2010-08-30 2016-05-05 Arzeda Corp. Fermentation route for the production of levulinic acid, levulinate esters, valerolactone, and derivatives thereof
US9346803B2 (en) 2011-10-17 2016-05-24 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
CN107011229B (zh) 2012-01-06 2019-11-05 诺华股份有限公司 杂环化合物和它们的使用方法
WO2013131235A1 (zh) * 2012-03-05 2013-09-12 大连理工大学 一类以萘为母体的双光子荧光探针、其制备方法及应用
TW202222786A (zh) 2016-02-01 2022-06-16 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
WO2018125992A1 (en) * 2016-12-28 2018-07-05 Promega Corporation Functionalized nanoluc inhibitors
EP4334285A1 (en) * 2021-05-05 2024-03-13 Kare Chemical Technologies Inc. Catalytic tryptamine processes and precursors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1482845A (fr) * 1964-12-31 1967-06-02 Merck & Co Inc Composés de l'indol
DK0431520T3 (da) * 1989-12-04 1995-04-10 Searle & Co Heterocycliske acylaminodiol-beta-aminosyrederivater
CA2074357A1 (fr) * 1990-03-07 1991-09-08 Jean-Dominique Bourzat Derives de glycinamide, leur preparation et les medicaments les contenant
US5312928A (en) * 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
EP0639567A1 (en) * 1992-05-08 1995-02-22 Otsuka Pharmaceutical Factory, Inc. Indole derivative
JPH0835029A (ja) * 1994-07-19 1996-02-06 Toyota Motor Corp 高強度高延性鋳造アルミニウム合金およびその製造方法

Also Published As

Publication number Publication date
ATE170839T1 (de) 1998-09-15
ES2122555T3 (es) 1998-12-16
US5877202A (en) 1999-03-02
FI963272A (fi) 1996-08-21
CA2183731A1 (en) 1995-08-24
DE69504637D1 (de) 1998-10-15
HUT76133A (en) 1997-06-30
JPH09509169A (ja) 1997-09-16
AU680740B2 (en) 1997-08-07
FI963272A0 (fi) 1996-08-21
DE69504637T2 (de) 1999-05-06
CA2183731C (en) 2000-03-21
DK0746544T3 (da) 1999-06-07
IL112700A0 (en) 1995-05-26
CN1141627A (zh) 1997-01-29
JP3536258B2 (ja) 2004-06-07
NZ281431A (en) 1997-09-22
EP0746544B1 (en) 1998-09-09
EP0746544A1 (en) 1996-12-11
KR100362864B1 (ko) 2003-04-16
AU1837395A (en) 1995-09-04
HU9602299D0 (en) 1996-10-28
NO963483D0 (no) 1996-08-21
WO1995022524A1 (en) 1995-08-24

Similar Documents

Publication Publication Date Title
NO963483D0 (no) Nye indolderivater som er anvendbare for å behandle östrogen-relaterte neoplasmer og forstyrrelser
Kadakia et al. The effect of hormones on the voice
NO985975L (no) Blandinger og fremgangsmÕter for frembringelse av farmakologisk aktive preparater og anvendelser derav
ATE228003T1 (de) Verwendung von cntf (ciliary neurotrophic factor) rezeptoraktivatoren fur behandlung von fettleibigkeit
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
TR200103104T2 (tr) Glukortikoid alıcı modülatörleri
NO981203L (no) Selektive <beta>3 -adrenergiske agonister
NO20055919L (no) 3-Subtituerte,5,6-Diaryl-Pyrazin-2-Karboksamid og 2-Sulfonamidderivater som CB1-Modulatorar
PT101087A (pt) Derivados de indole
DE69820632D1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)-piperazin-derivate
NO994901L (no) Behandling av sentralnerveforstyrrelser ved selektive östrogenreseptormodulatorer
EA200401078A1 (ru) Применение фитоэстрогенсодержащих экстрактов, селективно модулирующих бета-рецептор эстрогена
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE171873T1 (de) Antiglucocorticoidsteroide zur behandlung von angststörungen
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
DK1525215T3 (da) Modulatorer for receptoren for progesteron med forhöjet anti-gonadotrop aktivitet til fertilitetskontrol hos kvinder og ved terapi til erstatning af hormoner
NZ512923A (en) Potent sulfatase inhibitors that are metabolically stable, selective and devoid of estrogenic activity
DE60042446D1 (de) Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
BR0309032A (pt) Método para tratar sintomas vasomotores, a menopausa, deficiências hormonais em um paciente, e para tratar um paciente que sofre de sintomas vasomotores
NO980375L (no) Humant MP52 Arg protein
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
HUP0100742A2 (hu) Cikloprop[14,15]-ösztriol származékok alkalmazása a központi idegrendszerben az ösztrogénhiány pótlására szolgáló gyógyszerkészítmények előállítására
DE60003214D1 (de) Benz[f]indole zur verwendung in der behandlung von 5ht-rezeptor relatierten störungen